109.08 -0.24 (-0.22%)
Pre-Market: 8:30AM EST
|Bid||109.07 x 1800|
|Ask||109.52 x 2200|
|Day's Range||109.10 - 110.40|
|52 Week Range||58.59 - 110.70|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||13.44|
|Earnings Date||Jan 29, 2020 - Feb 3, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||103.40|
ServiceNow , the cloud computing company, was rising in in premarket trading Tuesday after it was announced the stock would join the S&P 500 index on Thursday. ServiceNow of Santa Clara, Calif., will replace Celgene , which is close to being acquired by Bristol-Myers Squibb , in the index, according to S&P Global. ServiceNow shares were rising 4.2% to $277.50 in premarket trading.
Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.
ServiceNow Inc. will replace Celgene Corp. in the S&P 500 index before the open on Thursday, S&P Global said late Monday. Bristol-Myers Squibb Co. is acquiring Celgene in a deal expected to close soon. Lab equipment maker Thermo Fisher Scientific Inc. will join the S&P 100, S&P Global said in the statement. ServiceNow, a cloud computing company based in Santa Clara, Calif., said earlier Monday that Gina Mastantuono will be its new chief financial officer effective Jan. 13. Shares were 4% higher in the extended session, after ending the regular trading day up 2.4%.
NEW YORK, Nov. 18, 2019 -- Nasdaq (Nasdaq: NDAQ) today announced that Exelon Corporation (Nasdaq: EXC), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the.
(BMY)announced on Friday that it expects to complete its acquisition of the biotech firm (CELG)on Wednesday, nearly a year after announcing the controversial deal. The completion comes after the Federal Trade Commission effectively cleared the merger in a statement on Friday. As a condition of the deal, the FTC required Bristol-Myers (ticker: BMY) and Celgene (CELG) to sell the rights to Otezla, Celgene’s psoriasis drug.
In our opinion one of the best tools for ordinary investors who are on the hunt for new ideas is 13F filings. Once every quarter hedge funds with at least $100 million in total positions in publicly traded US stocks are required to open the kimono and disclose the number of shares and the total […]
Celgene Corp. is required to divest its most popular psoriasis treatment in order to be acquired by Bristol-Myers Squibb Co. , the Federal Trade Commission announced Friday. For Bristol-Myers to close on its $74 billion acquisition, Celgene will have to sell its drug Otezla for $13.4 billion to Amgen Inc. , the FTC said. "The Commission has ordered BMS to divest Otezla to preserve BMS's incentive to continue developing its own oral product for treating moderate-to-severe psoriasis," said FTC Chairman Joseph Simons in a statement. "The antitrust laws protect not only competition today, but competition in the future, especially when it comes to the development of new treatments for chronic conditions." The companies already anticipated the FTC's concerns and agreed to the deal back in August.
Bristol-Myers Squibb and Celgene said late Friday the U.S. Federal Trade Commission cleared their looming merger. BMY stock rose a fraction in late trading. Celgene stock was unmoved.
Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. Bristol-Myers Squibb said the decision meant it had all the needed regulatory approvals and would close the acquisition on Wednesday.
Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. Bristol-Myers Squibb said the decision meant it had all the needed regulatory approvals and would close the acquisition on Wednesday. Amgen has agreed to buy Celgene's Otezla business, the company said in a statement.
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and selling. Takeaways From ...
REVLIMID® and rituximab has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond
US drug regulators have issued their first ever approval for a Chinese-developed innovative cancer treatment, marking a breakthrough for the country’s biotech sector. The US Food and Drug Administration approved zanubrutinib, a treatment for mantle cell lymphoma, a rare kind of blood cancer, produced by BeiGene in Beijing under the name Brukinsa. Since 2015, Beijing has accelerated approvals of drugs developed by local biotech companies.
Pharmaceutical company Bristol-Myers has been in a downtrend since 2016 and after unveiling its planned merger with Celgene. Is now the right time to buy BMY stock?
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.